AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33593768
Drug: Standard praziquantel
RxNorm normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard praziquantel (PZQ) treatment
Trial: 36125447
Drug: TRM (δ-tocotrienol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRM (δ-tocotrienol 250 mg; resveratrol 150 mg)
Trial: 36125447
Drug: Placebo (cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (cellulose 400 mg)
Trial: 34410414
Drug: Standard antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antiplatelet treatment
Trial: 36068181
Drug: Behavioural intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Behavioural intervention to increase physical activity in daily living (PADL)
Trial: 32960643
Drug: BCAA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCAA supplementation (21 g over a week, 7 g per day on Monday, Wednesday, and Friday)
Trial: 33012654
Drug: Migalastat 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Migalastat 150 mg every other day (QOD)
Trial: 32539786
Drug: Oral non-absorbable
RxNorm normalized name: Tavist Non-Sedating Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral non-absorbable antibiotic prophylaxis (OAP) with tobramycin and colistin for three days preoperatively
Trial: 35723850
Drug: Thymus kotschyanus
RxNorm normalized name: THYMUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymus kotschyanus extract (0.5 g/day)
Trial: 35553446
Drug: TRF with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRF with whey protein supplementation (25 g/d)
Trial: 34061178
Drug: Left-sided KRAS
RxNorm normalized name: cured fat, pork side bacon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Left-sided KRAS wild-type tumors receiving anti-EGFR treatment
Trial: 35482567
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose dexmedetomidine (0.04 mg/kg, IM) + midazolam (3 mg/kg, IM)
Trial: 35482567
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose dexmedetomidine (0.01 mg/kg, IM) + midazolam (3 mg/kg, IM)
Trial: 32657946
Drug: Reltecimod (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reltecimod (0.5 mg/kg)
Trial: 36496349
Drug: DWP16001 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWP16001 2 mg with gemigliptin (50 mg once-daily) and metformin (1000 mg twice-daily)
Trial: 36496349
Drug: DWP16001 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWP16001 2 mg without gemigliptin and metformin
Trial: 32618438
Drug: Marketed 150
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marketed 150 mg peficitinib tablet under fasted conditions
Trial: 32618438
Drug: Marketed 150
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marketed 150 mg peficitinib tablet under fed conditions
Trial: 32618438
Drug: Marketed 150
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marketed 150 mg peficitinib tablet
Trial: 34749425
Drug: Intensive olfactory
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive olfactory training (IOT) - twice a day with a 40-odor set for 15 days
Trial: 33116470
Drug: Systemic steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic steroid therapy administered to 658 patients (53%)
Trial: 33116470
Drug: Non-steroid users
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-steroid users
Trial: 34236951
Drug: Control condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control condition of an occupational therapy driving intervention
Trial: 32849284
Drug: Nutraceutical containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutraceutical containing Bergamot polyphenol fraction and Cynara Cardunculus extract, 300 mg/day for 12 weeks
Trial: 35622972
Drug: Pacritinib (PAC)
DrugBank: Pacritinib (DB11697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pacritinib (PAC) 400 mg daily in PERSIST-1
Trial: 35622972
Drug: Pacritinib (PAC)
DrugBank: Pacritinib (DB11697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pacritinib (PAC) 400 mg daily or 200 mg twice daily in PERSIST-2
Trial: 35622972
Drug: Pacritinib (PAC)
DrugBank: Pacritinib (DB11697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pacritinib (PAC) 200 mg twice daily in PAC203 study
Trial: 34979178
Drug: Daily steps
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily steps (average 3,460 ± 1,768 steps per day)
Trial: 35353553
Drug: Treatment arm
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment arm assignment
Trial: 35353553
Drug: Enrollment in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enrollment in treatment arms
Trial: 34310692
Drug: Rocuronium 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.6 mg·kg-1
Trial: 34310692
Drug: Remifentanil 2
RxNorm normalized name: remifentanil 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 2 µg·kg-1
Trial: 35313351
Drug: Auditory naming-related
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auditory naming-related high gamma augmentation
Trial: 35313351
Drug: Picture naming-related
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Picture naming-related high gamma augmentation
Trial: 35313351
Drug: Naming-related low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naming-related low gamma augmentation and alpha/beta attenuation
Trial: 34433897
Drug: Bacillus pumilus
RxNorm normalized name: Bacillus pumilus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacillus pumilus inoculated seeds at 0.25 mg kg‐1 of CdSO4
Trial: 34433897
Drug: Bacillus pumilus
RxNorm normalized name: Bacillus pumilus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacillus pumilus uninoculated seeds at 0.75 mg kg‐1 of CdSO4
Trial: 35594778
Drug: e‐CBT‐I (internet-delivered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: e‐CBT‐I (internet-delivered cognitive-behavioral therapy for insomnia)
Trial: 33532995
Drug: Ketamine (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.25 mg·kg−1 bolus before surgery, followed by 0.05 mg·kg−1·hr−1 infusion until end of surgery)
Trial: 35270624
Drug: Acetaminophen (ACT)
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (ACT) 500 mg, three caplets
Trial: 35270624
Drug: Placebo (PLA),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PLA), three gelatin capsules
Trial: 36750617
Drug: First-line pembrolizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First-line pembrolizumab monotherapy
Trial: 36401407
Drug: Sopoongsan (treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sopoongsan (treatment group, n = 10)
Trial: 35467095
Drug: Docetaxel treatment
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel treatment in mCRPC patients
Trial: 35467095
Drug: Docetaxel treatment
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel treatment in mHSPC patients
Trial: 34400961
Drug: Olanzapine (0.14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (0.14 mg/kg)
Trial: 32036964
Drug: CUR (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CUR (400 mg/kg curcumin)
Trial: 32036964
Drug: OTA +
RxNorm normalized name: Otamixaban
DrugBank: Otamixaban (DB06635)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OTA + CUR (2 mg/kg OTA plus 400 mg/kg curcumin)
Trial: 32036964
Drug: OTA (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OTA (2 mg/kg OTA)
Trial: 35659763
Drug: Radiofrequency turbinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiofrequency turbinate reduction followed by intranasal steroid and Antihistamine H-1 (AH-1)
Trial: 35659763
Drug: Intranasal steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal steroid and Antihistamine H-1 (AH-1)
Trial: 35241426
Drug: deucravacitinib 6
RxNorm normalized name: deucravacitinib 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: deucravacitinib 6 mg once a day
Trial: 35241426
Drug: deucravacitinib 12
RxNorm normalized name: Deucravacitinib
DrugBank: Deucravacitinib (DB16650)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: deucravacitinib 12 mg once a day
Trial: 33051119
Drug: NLP algorithms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NLP algorithms for detecting implant model
Trial: 32811464
Drug: Dance Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dance Group (DG) - Brazilian dance program inspired by Samba and Forró rhythms, 24 sessions of 1 hour each, twice per week for 12 weeks.
Trial: 35763398
Drug: Socket shield
RxNorm normalized name: Peroxy Shield
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Socket shield technique with immediate implant placement in contact (Group A)
Trial: 35763398
Drug: Socket shield
RxNorm normalized name: Peroxy Shield
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Socket shield technique with immediate implant placement leaving a gap (Group B)
Trial: 36332653
Drug: Combination prevention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination prevention intervention with universal antiretroviral therapy (ART; arm A)
Trial: 36438688
Drug: Camrelizumab (SHR‐1210)
RxNorm normalized name: Ocrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Camrelizumab (SHR‐1210) combined with gemcitabine plus cisplatin (GP) chemotherapy
Trial: 37280275
Drug: Gemcitabine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine plus cisplatin (GP) chemotherapy
Trial: 36212931
Drug: Lidocaine infusion
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine infusion (2 mg/kg bolus over 5 minutes, then 1.5 mg/kg/h infusion)
Trial: 36212931
Drug: Dexamethasone (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (0.15 mg/kg over 5 minutes, followed by saline)
Trial: 35999678
Drug: Intranasal fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal fentanyl (1 μg/kg) combined with oral midazolam (0.7 mg/kg)
Trial: 35999678
Drug: Oral midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral midazolam (0.7 mg/kg) alone
Trial: 34380301
Drug: Low-calorie diet
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-calorie diet (LCD), physical exercises in the gym, daily walking up to 3-5 km/day
Trial: 34380301
Drug: Low-calorie diet
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-calorie diet (LCD), physical exercises in the gym, daily walking up to 3-5 km/day, nutraceutical correction
Trial: 35749413
Drug: 12-week Tai
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week Tai Chi program (45 minutes per session, twice a week)
Trial: 34873674
Drug: GSK2256294 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2256294 (10 mg once daily for 10 days)
Trial: 33629110
Drug: Anifrolumab 300
RxNorm normalized name: ANIFROLUMAB 300 mg in 2.0 mL INTRAVENOUS INJECTION, SOLUTION [SAPHNELO]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anifrolumab 300 mg every 4 weeks
Trial: 35830070
Drug: Acaulospora longula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acaulospora longula treatments
Trial: 35830070
Drug: G. albida
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G. albida + Bradyrhizobium BR 3267
Trial: 33528904
Drug: Empagliflozin (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin (25 mg/day) with no meal announcement
Trial: 33528904
Drug: Empagliflozin (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin (25 mg/day) with simple meal announcement
Trial: 34981490
Drug: Lentil group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lentil group (500 mg of lentil powder daily for 3 months)
Trial: 34981490
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (placebo daily for 3 months)
Trial: 32503494
Drug: Trimetazidine (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine (35 mg twice a day)
Trial: 35729250
Drug: L-menthol (n=26)
DrugBank: Levomenthol (DB00825)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-menthol (n=26)
Trial: 35729250
Drug: L-menthol
RxNorm normalized name: L-menthol
DrugBank: Levomenthol (DB00825)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-menthol
Trial: 34250817
Drug: Liraglutide (glucagon-like
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (glucagon-like peptide-1 receptor agonist)
Trial: 36036907
Drug: Lumbar epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumbar epidural steroid injections (LESIs)
Trial: 36036907
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment in the RCT of LESI
Trial: 35866910
Drug: Baricitinib in
RxNorm normalized name: Product containing baricitinib in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baricitinib in combination with topical corticosteroids
Trial: 33200220
Drug: Baricitinib 4
RxNorm normalized name: baricitinib 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baricitinib 4 mg (+MTX)
Trial: 33200220
Drug: Placebo (+MTX)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (+MTX) switched to Baricitinib 4 mg (+MTX)
Trial: 32811629
Drug: Take-home naloxone
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Take-home naloxone (THN) administration with positive communication
Trial: 32811629
Drug: Take-home naloxone
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Take-home naloxone (THN) administration with negative communication
Trial: 34431970
Drug: IL-6 levels
RxNorm normalized name: IL-6
DrugBank: Human interleukin-6 (DB15060)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-6 levels ≥2.0 ng/L
Trial: 32749173
Drug: Oral EGCG
RxNorm normalized name: EGCG
DrugBank: Epigallocatechin gallate (DB12116)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral EGCG 100 mg twice daily for 10 days
Trial: 33629114
Drug: Aromatase inhibitors
RxNorm normalized name: Aromatase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase inhibitors (AIs) adherence
Trial: 33262578
Drug: Evogliptin 5
RxNorm normalized name: alogliptin 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evogliptin 5 mg alone (EVO)
Trial: 33262578
Drug: Glimepiride 4
RxNorm normalized name: glimepiride 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride 4 mg alone (GLI)
Trial: 33262578
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of evogliptin and glimepiride (EVO+GLI)
Trial: 35622848
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (iNO) as an adjunct to standard of care with medical oxygen
Trial: 34024187
Drug: Iodine excretion
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iodine excretion level in urine among school-aged children
Trial: 34024187
Drug: Iodine excretion
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iodine excretion level in urine among pregnant women
Trial: 36153475
Drug: Itacitinib (a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itacitinib (a selective JAK1 inhibitor) combined with ASTX727 (a fixed dose oral combination of decitabine and cedazuridine)
Trial: 32385845
Drug: 0.2% sirolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% sirolimus gel
Trial: 34627832
Drug: Serratus anterior
RxNorm normalized name: Fucus serratus extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serratus anterior plane block (SAPB) with 0.4 mL.kg-1 0.5% ropivacaine
Trial: 32359776
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg intravenous dexketoprofen trometamol
Trial: 32359776
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg dexketoprofen trometamol + 10 mg metoclopramide
Trial: 32131911
Drug: CORDIAL program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CORDIAL program (11 individual weekly sessions of CBT, cognitive rehabilitation, and reminiscence therapy)
Trial: 32131911
Drug: Treatment-as-usual (Control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-usual (Control group)
Trial: 34636493
Drug: Q-switched Nd:YAG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Q-switched Nd:YAG laser with daily 3% tranexamic acid gel
Trial: 34636493
Drug: Microneedling with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microneedling with daily 3% tranexamic acid gel
Trial: 32727548
Drug: Simparica Trio®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simparica Trio® (combination of sarolaner, moxidectin, and pyrantel)
Trial: 34971551
Drug: KUR-113 (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KUR-113 (0.4 mg/mL)
Trial: 34971551
Drug: KUR-113 (0.133
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KUR-113 (0.133 mg/mL)
Trial: 34971551
Drug: KUR-113 (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KUR-113 (1.0 mg/mL)
Trial: 32168551
Drug: Palonosetron 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palonosetron 0.75 mg (day 1) combined with dexamethasone and fosaprepitant
Trial: 32168551
Drug: Granisetron 1
RxNorm normalized name: granisetron 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron 1 mg (day 1) combined with dexamethasone and fosaprepitant
Trial: 35104166
Drug: Insulin pump
RxNorm normalized name: insulin pump syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin pump infusion sets (various types)
Trial: 35104166
Drug: Insulin pump
RxNorm normalized name: insulin pump syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin pump infusion sets (90° Teflon)
Trial: 35104166
Drug: Insulin pump
RxNorm normalized name: insulin pump syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin pump infusion sets (angled Teflon)
Trial: 35104166
Drug: Insulin pump
RxNorm normalized name: insulin pump syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin pump infusion sets (steel)
Trial: 35428722
Drug: SEC 300
RxNorm normalized name: sec-laureth-9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SEC 300 mg
Trial: 35428722
Drug: SEC 150
RxNorm normalized name: sec-laureth-9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SEC 150 mg
Trial: 32199095
Drug: Rituximab (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (375 mg/m2 administered intravenously every week for 4 weeks, then 1000 mg every 2 weeks at 24 weeks and 48 weeks after randomisation)
Trial: 32199095
Drug: Placebo (matching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (matching intravenous administration)
Trial: 35527576
Drug: Intensive computer-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive computer-based cognitive program using REHACOM software in addition to conventional physical therapy (aerobic training, resistive training, flexibility program)
Trial: 35527576
Drug: Conventional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional physical therapy program for MS including aerobic training, resistive training, flexibility program and placebo cognitive sessions
Trial: 33001537
Drug: Topical TCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical TCA 35%
Trial: 36411567
Drug: Atypical antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atypical antipsychotics (risperidone 2‐6 mg/d, olanzapine 5‐20 mg/d, quetiapine 400‐750 mg/d, aripiprazole 10‐30 mg/d, ziprasidone 80‐160 mg/d)
Trial: 36411567
Drug: Typical antipsychotics
RxNorm normalized name: benzocaine Mucous Membrane Topical Solution [Topicale]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Typical antipsychotics (perphenazine 20‐60 mg/d, haloperidol 6‐20 mg/d)
Trial: 32744358
Drug: metformin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metformin + placebo
Trial: 33279854
Drug: Durvalumab (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab (1500 mg at day 1 of each cycle) and Tremelimumab (75 mg at day 1 for 4 cycles) - Arm A
Trial: 33279854
Drug: Durvalumab, Tremelimumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab, Tremelimumab with Paclitaxel (80 mg/m2 at D1, D8, D15) - Arm B
Trial: 32609960
Drug: INP105 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INP105 5 mg
Trial: 32609960
Drug: INP105 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INP105 10 mg
Trial: 32609960
Drug: INP105 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INP105 15 mg
Trial: 32609960
Drug: OLZ IM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OLZ IM 5 mg
Trial: 32609960
Drug: OLZ IM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OLZ IM 10 mg